Genentech costs hit Roche earnings
China Daily | Updated:  2009-07-24 08:04
 
| 
 
 An employee checks capsules of Roche's influenza drug Tamiflu. Bloomberg News  | 
BASEL, Switzerland: Roche, the maker of the Tamiflu flu drug, missed forecasts with a 29 percent drop in first-half net profit, hit by costs related to its $47 billion acquisition of Genentech.
Photo
















